Protein arginine methyltransferase 5 (PRMT5), an important arginine methyltransferase linked to tumor initiation and progression, has been reported to promote ferroptosis resistance in TNBC while impairing ferroptosis resistance in other breast cancer subtypes [118]. Here, PRMT5 is linked to breast carcinoma.